<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&#13;
&lt;table id="schedule" cellspacing="0" cellpadding="2" summary="This table shows the date, time, and location of the meeting" border="0" style="width: 643px"&gt;&#13;
    &lt;tbody&gt;&#13;
        &lt;tr id="rrtr0"&gt;&#13;
            &lt;th id="a1" valign="top" align="left" bgcolor="#cccccc" style="width: 71px"&gt;Center&lt;/th&gt;&#13;
            &lt;th id="a2" valign="top" align="left" bgcolor="#cccccc" style="width: 158px"&gt;Date&lt;/th&gt;&#13;
            &lt;th id="a3" valign="top" align="left" bgcolor="#cccccc" style="width: 172px"&gt;Time&lt;/th&gt;&#13;
            &lt;th id="a4" valign="top" align="left" bgcolor="#cccccc" style="width: 238px"&gt;Location&lt;/th&gt;&#13;
        &lt;/tr&gt;&#13;
        &lt;tr id="rrtr1"&gt;&#13;
            &lt;td id="rrtd0" valign="top" headers="a1" height="61" style="width: 71px"&gt;CDER&lt;/td&gt;&#13;
            &lt;td id="rrtd1" valign="top" headers="a2" style="width: 158px"&gt;October 24, 2013&amp;nbsp;&lt;/td&gt;&#13;
            &lt;td id="rrtd2" valign="top" headers="a3" style="width: 172px"&gt;8:00 a.m. to 5:00 p.m.&lt;br /&gt;&#13;
            &amp;nbsp;&lt;/td&gt;&#13;
            &lt;td id="rrtd3" valign="top" headers="a4" style="width: 238px"&gt;&#13;
            &lt;div&gt;Sheraton Silver Spring Hotel&lt;/div&gt;&#13;
            &lt;div&gt;Cypress Ballroom&lt;/div&gt;&#13;
            &lt;div&gt;8777 Georgia Avenue&lt;/div&gt;&#13;
            &lt;div&gt;Silver Spring, Maryland&lt;/div&gt;&#13;
            &lt;/td&gt;&#13;
        &lt;/tr&gt;&#13;
    &lt;/tbody&gt;&#13;
&lt;/table&gt;&#13;
&lt;/p&gt;&#13;
&lt;p&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/p&gt;&#13;
&lt;p&gt;The committee will discuss a new drug application (NDA) 205123, simeprevir (a hepatitis C virus protease inhibitor), manufactured by Janssen Pharmaceutical Co., with a proposed indication for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin (two medicines approved to treat chronic hepatitis C) in adult patients with compensated liver disease (including cirrhosis) who are treatment-na&amp;iuml;ve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Compensated liver disease is a stage in which the liver is damaged but maintains ability to function.&lt;/p&gt;&#13;
&lt;p&gt;&lt;strong&gt;Meeting Materials&lt;/strong&gt;&lt;/p&gt;&#13;
&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting.&amp;nbsp; If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&amp;nbsp;&lt;/p&gt;&#13;
&lt;p&gt;Background material is available at:&lt;/p&gt;&#13;
&lt;ul sizset="41" sizcache="1"&gt;&#13;
    &lt;li sizset="41" sizcache="1"&gt;&lt;a href="http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/ucm368547.htm"&gt;2013 Meeting Materials, Antiviral Drugs Advisory Committee&lt;/a&gt;&amp;nbsp;&lt;/li&gt;&#13;
&lt;/ul&gt;&#13;
&lt;p&gt;&lt;strong&gt;Public Participation Information&lt;/strong&gt;&lt;/p&gt;&#13;
&lt;div&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/div&gt;&#13;
&lt;ul&gt;&#13;
    &lt;li&gt;Written submissions may be made to the contact person on or before&amp;nbsp;October 9, 2013.&lt;/li&gt;&#13;
    &lt;li&gt;Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m on October 24, 2013. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before October 1, 2013.&lt;/li&gt;&#13;
&lt;/ul&gt;&#13;
&lt;p&gt;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by October 2, 2013.&lt;/p&gt;&#13;
&lt;p&gt;&lt;strong&gt;Webcast Information&lt;/strong&gt;&lt;/p&gt;&#13;
&lt;p&gt;CDER does not provide webcasts of advisory committee meetings that are held at venues other than the FDA White Oak Conference Center. Therefore, CDER will not be providing a webcast of the October 24, 2013 Antiviral Drugs Advisory Committee meeting.&lt;/p&gt;&#13;
&lt;p&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt;&#13;
&lt;ul sizset="42" sizcache="1"&gt;&#13;
    &lt;li sizset="42" sizcache="1"&gt;Karen Abraham-Burrell, PharmD&lt;br /&gt;&#13;
    Center for Drug Evaluation and Research&lt;br /&gt;&#13;
    Food and Drug Administration&lt;br /&gt;&#13;
    10903 New Hampshire Avenue &lt;br /&gt;&#13;
    WO31-2417&lt;br /&gt;&#13;
    Silver Spring, MD&amp;nbsp;20993-0002&lt;br /&gt;&#13;
    Phone:&amp;nbsp;301-796-9001&lt;br /&gt;&#13;
    FAX: &amp;nbsp;301-847-8533&lt;br /&gt;&#13;
    Email: &amp;nbsp;&lt;a title="mailto:AVAC@fda.hhs.gov" href="mailto:AVAC@fda.hhs.gov"&gt;&lt;u&gt;&lt;font color="#0000ff"&gt;AVAC@fda.hhs.gov&lt;/font&gt;&lt;/u&gt;&lt;/a&gt;&amp;nbsp;&lt;/li&gt;&#13;
&lt;/ul&gt;&#13;
&lt;ul&gt;&#13;
    &lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;&#13;
    1-800-741-8138 (301-443-0572 in the Washington DC area) &lt;br /&gt;&#13;
    Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&#13;
&lt;/ul&gt;&#13;
&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.&amp;nbsp;Therefore, you should always check the agency&amp;rsquo;s Website and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&#13;
&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.&amp;nbsp;FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs.&amp;nbsp;If you require special accommodations due to a disability, please contact Karen Abraham-Burrell at (301) 796-9001 at least 7 days in advance of the meeting.&amp;nbsp;&lt;/p&gt;&#13;
&lt;p sizset="43" sizcache="1"&gt;FDA is committed to the orderly conduct of its advisory committee meetings.&amp;nbsp;Please visit our Web site at &lt;a target="" href="http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm"&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&#13;
&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
